ProSomnus — SPAC Merger (May 2022)
38 slides from ProSomnus's SPAC merger presentation, May 10, 2022
Slide 1: Company Introduction May 2022
STRICTLY CONFIDENTIAL Company Introduction May 2022
Slide 2: Disclaimer
STRICTLY CONFIDENTIAL 2 Disclaimer This presentation is for informational purposes only and has been prepared to assist interested parties in making their own e val uation with respect to the proposed business combination between Lakeshore Acquisition I Corp. (“Lakeshore”) and ProSomnus Holdings Inc
Slide 3: Disclaimer (cont.): Use of Projections and Non-GAAP Measures
STRICTLY CONFIDENTIAL 3 Disclaimer (cont.) Use of Projections and Non - GAAP Measures This presentation is for informational purposes only and has been prepared to assist interested parties in making their own e val uation with respect to the proposed business combination between Lakeshore Acquisiti
Slide 4: Key Messages
STRICTLY CONFIDENTIAL 4 Large, growing, underserved disease with significant comorbidities Limitations of current therapies (CPAP) result in inadequate alleviation, and do not offer the remote physiologic monitoring data that physicians need to better manage the disease ProSomnus is a pioneer of pre
Slide 5: ProSomnus is Changing the Way OSA is Treated
STRICTLY CONFIDENTIAL 5 x ProSomnus precision devices are individualized to match the patient’s anatomy and treatment plan with precision (less than 0.5 millimeters variance to the prescription) x Precision enables better effectiveness, fewer side effects and greater patient satisfaction x Clinicall
Slide 6: Significant Disruption of OSA Market is Set to Occur
STRICTLY CONFIDENTIAL 6 CPAP Significant Disruption of OSA Market is Set to Occur Which would you choose? Low patient adherence Social stigma surrounding therapy Discomfort, confinement Occurrence of upper airway infection, dry - throat and nasal skin irritation Manual, time - intensive cleaning reg
Slide 7: Initiatives Underway to Drive Potential Significant Growth
STRICTLY CONFIDENTIAL 7 Initiatives Underway to Drive Potential Significant Growth North America Sales Force Expansion International Expansion Direct - to - Consumer Marketing and Clinician Education Launch of Novel Continuous Patient Monitoring Device Future Product Opportunities: Adjacent Medical
Slide 8: OSA is Highly Prevalent and Associated with Major Health Consequences
STRICTLY CONFIDENTIAL 8 OSA is Highly Prevalent and Associated with Major Health Consequences ▪ OSA is the recurrent collapse of the airway during sleep resulting in oxygen shortages and subconscious arousals ▪ OSA is associated with comorbidities and excessive daytime sleepiness ▪ CPAP, which force
Slide 9: OSA Patient Population Funnel
STRICTLY CONFIDENTIAL 9 Failed CPAP North American CPAP Users North American OSA Diagnoses North American OSA Sufferers Global OSA Sufferers >1bn 1 ~74mm 2 ~18mm 3 ~15mm 4 ~7mm 6 1. Benjafield AV et al. Estimation of the global prevalence and burden of obstructive sleep apnoea : a literature - based
Slide 10: Medical Insurance Reimbursement Economics are Attractive for all Stakeholders
STRICTLY CONFIDENTIAL 10 Medical Insurance Reimbursement Economics are Attractive for all Stakeholders Surgery / Upper Airway Stimulation CPAP OAT Selection of Treatment Modality ENT Respiratory Therapist Medical Insurance & Pre - Approval Dental Sleep Provider OAT Fitting & Titration Evaluation Dia
Slide 11: Effectiveness of Incumbent Therapies is Limited
STRICTLY CONFIDENTIAL 11 85% 74% 50% 48% 45% ProSomnus (Mild/Moderate) ProSomnus (All Severities) CPAP Upper Airway Stimulation Legacy OAT Effectiveness of Incumbent Therapies is Limited ProSomnus has superior effectiveness over incumbent therapies 1. ProSomnus adherence: Stern, J. Efficacy and Effe
Slide 12: ProSomnus Meets AASM Gold Standard for Adherence
STRICTLY CONFIDENTIAL 12 5.7 Hours 4.5 Hours 7.2 Hours Legacy OAT Upper Airway Stimulation CPAP ProSomnus We Believe That ProSomnus is the Only Therapy That Meets AASM Gold Standard for Adherence ProSomnus devices are biomechanically designed to address CPAP’s limitations on adherence, leading to a
Slide 13: ProSomnus Efficacy Comparable to CPAP for Mild and Moderate OSA
STRICTLY CONFIDENTIAL 13 56% 90% 94% Legacy OAT Upper Airway Stimulation CPAP ProSomnus 1. Mosca et al. JCSM 2022; 18(3):911 - 919. 2. Dieltjens M, Vanderveken O. Oral Appliances in Obstructive Sleep Apnea . Healthcare (Basel). 2019 Nov 8 3. Benjafield AV, et al. 2019 Aug 7, assumed even split betwe
Slide 14: ProSomnus Delivers Outstanding Clinical Results and Patient Preferred Experience
STRICTLY CONFIDENTIAL 14 Prescription Drivers Definition CPAP Legacy OAT: Arbitrary Jaw Thrust Legacy OAT: Jaw Expansion ProSomnus Precision OAT Nightly disease symptom resolution Disease symptom alleviation in lab, single night Nightly adherence with treatment plan Introduction o f secondary, undes
Slide 15: The ProSomnus Difference: Precision, Personalized Sleep Medicine Therapy
STRICTLY CONFIDENTIAL 15 The ProSomnus Difference: Precision, Personalized Sleep Medicine Therapy ProSomnus manufactures one of the only devices to meet AADSM standards Prescription Transfer Error (in millimeters) 1 Efficacy Loss % as a Function of Prescription Transfer Error 2 Guidelines Establish
Slide 16: Proprietary, Digital Manufacturing Capabilities
STRICTLY CONFIDENTIAL 16 Proprietary, Digital Manufacturing Capabilities Enable ProSomnus’s Precision Performance Advantages Utility patents cover unique product features, methods and processes, with 8 granted and 15 pending Tailored in - house manufacturing processes and patented, proprietary techn
Slide 17: Next Gen Device with Continuous Physiologic Monitoring
STRICTLY CONFIDENTIAL 17 ProSomnus Next Gen Device with Continuous Physiologic Monitoring Poised to Change Sleep Medicine Patent pending, FDA cleared, soft launch expected in Q4 2022 ▪ Device with embedded sensor enables continuous remote monitoring of medically necessary physiologic metrics Adheren
Slide 18: Pull Patients to Dentists, Push ProSomnus to Providers
STRICTLY CONFIDENTIAL 18 Sales Objective: ▪ Educate & Engage ▪ 2 Call Points: Physicians & Dental Providers Build a bi - directional referral relationship ▪ Shift prescriptions from CPAP to ProSomnus Pull Patients to Dentists and Sleep Physicians ▪ Brand of choice for OSA treatment and increase traf
Slide 19: Growing Library of Evidence
STRICTLY CONFIDENTIAL 19 Growing Library of Evidence Indicating ProSomnus’s Performance EFFECTS Study 2 Effective front - line therapy for Mild/Moderate patients or Severe who refuse CPAP June 2021 SLEEP Journal, Vol. 44 Abstract #434 3 Precision oral appliance is capable of successfully treating pa
Slide 20: Medical Affairs: Active Studies
STRICTLY CONFIDENTIAL 20 Medical Affairs: Active Studies Study Objective Design Status Expected Next Steps Compare the efficacy of ProSomnus with CPAP as frontline therapy Prospective, controlled, cross over trial 40/121 patients enrolled Preliminary data available in Q4 ‘22 Secure FDA severe OSA in
Slide 21: Exceptional Management Team with Deep Medical and Dental Device Expertise
STRICTLY CONFIDENTIAL 21 ProSomnus’s management team has experience disrupting industries with breakthrough innovations Exceptional Management Team with Deep Medical and Dental Device Expertise ▪ Founding member of ProSomnus ▪ Previously was the President of MicroDental Laboratories ▪ Prior to Micro
Slide 22: Significant Growth Potential and Attractive Financial Prospects
STRICTLY CONFIDENTIAL 22 50% 52% ~59% ~65% 2020A 2021A 2022E 2023E $8 $14 $20 - 21 $38 - 40 2020A 2021A 2022E 2023E Significant Growth Potential and Attractive Financial Prospects GROSS MARGIN (2020A – 2023E) CAGR ~70% NET REVENUE (2020A – 2023E) ($ in millions) KEY REVENUE DRIVERS 70% Growth Rate ~
Slide 23: Transaction Summary
STRICTLY CONFIDENTIAL 23 56% 32% 6% 5% 2% PRO FORMA OWNERSHIP Existing ProSomnus Shareholders 56% Existing Lakeshore Shareholders (4) 32% Lakeshore Sponsor 6% Fees & Expenses (in stock) 5% Lenders (5) 2% Total Uses 100% Transaction Summary (1)(2) PRO FORMA VALUATION SUMMARY in millions (except per s
Slide 24: Select Public Comparables
STRICTLY CONFIDENTIAL 24 Select Public Comparables Source: Company filings, Wall Street Research and Capital IQ estimates as of May 6, 2022 1. 2023E Growth Adjusted Revenue Multiple calculated as EV / 2023E Revenue divided by 2021E – 2023E Revenue CAGR EV / ’23E Revenue Multiple ’21E – ’23E Revenue
Slide 25: An Opportunity to Transform the OSA Market
STRICTLY CONFIDENTIAL 25 OSA is a Massive, Rapidly Growing and Underserved Market ProSomnus Precision OAT Devices Deliver a Patient - Preferred, Clinically Proven and More Economical Treatment Patented, Innovative Technologies & Digital Capabilities Create More Effective & Preferred Outcomes Efficie
Slide 26: Appendix
STRICTLY CONFIDENTIAL Appendix “The precision engineering used in fabricating ProSomnus Medical Devices is second to none . They make me a better sleep dentist.” - B. Kent Smith, DDS, D.ABDSM, D.ASBA
Slide 27: Incumbent Therapy Limitations
STRICTLY CONFIDENTIAL 27 Forces Air Down Throat Positions Jaw Forward Arbitrary Jaw Thrust Surgical Implant Stimulates Tongue Mild, Moderate & Severe Mild & Moderate Moderate & Severe (Failed CPAP) Low adherence rates (<50% at 6 months) Expensive Discomfort Mask leakage Social stigma Limited portabi
Slide 28: Effectiveness, Satisfaction, Cost and Side Effects by Therapy
STRICTLY CONFIDENTIAL 28 $1.30 $2.99 $3.23 $41.10 ProSomnus OAT CPAP Legacy OAT Neurostimulation ▪ Effectiveness is a key driver of treatment selection for physicians and patients ▪ The effectiveness advantage of ProSomnus devices is a function of: Significantly better adherence rates Strong efficac
Slide 29: Low Adherence Limits Effectiveness of CPAP Therapy
STRICTLY CONFIDENTIAL 29 3.9 Hours 4.5 Hours 7.2 Hours CPAP: 1999 CPAP: 2019 ProSomnus Low Adherence Limits Effectiveness of CPAP Therapy CPAP is the current leading therapy for OSA, but inherent design flaws and patient - experience drawbacks mean adherence (hours worn) has barely changed in 20 yea
Slide 30: ProSomnus is NOT Like Other OATs
STRICTLY CONFIDENTIAL 30 Competitor #2 ProSomnus is NOT Like Other OATs ProSomnus device technology addresses the limitations of legacy OATs and results in superior performance DATA SUPPORTS PROSOMNUS HAS A SUPERIOR PRODUCT 1 NORTH AMERICAN REVENUE GROWTH VS. OAT COMPETITOR 1. Ramar K, Dort LC, Katz
Slide 31: Why are Patients More Adherent With ProSomnus Devices?
STRICTLY CONFIDENTIAL 31 0.0 0.0 0.0 0.0 0.8 0.5 1.6 0.7 Change in Lower Incisors Change in Upper Incisors Change in Overjet Change in Overbite Why are Patients More Adherent With ProSomnus Devices? Smaller & More Comfortable More Hygienic Fewer Side Effects ProSomnus devices allow for significantly
Slide 32: Why is ProSomnus More Efficacious Than Legacy OAT?
STRICTLY CONFIDENTIAL 32 Why is ProSomnus More Efficacious Than Legacy OAT? Precision Prescription Transfer Titration Mechanism Innovation Precision Anatomical Device Design Proprietary manufacturing technology enables ~7x more accurate prescription transfer Patented titration mechanism mitigates ri
Slide 33: ProSomnus Was Purposefully Designed To Be Different From Other OATs
STRICTLY CONFIDENTIAL 33 Arbitrary Jaw Thrust Arbitrary Jaw Thrust Arbitrary Jaw Thrust Jaw Expansion Precision Jaw Repositioning x x x x x x x x x x x x x ProSomnus Was Purposefully Designed To Be Different From Other OATs OSA Biomechanical Design Precision Manufactured AASM / AADSM 1 Recognized Sc
Slide 34: The ProSomnus Product Portfolio
STRICTLY CONFIDENTIAL 34 The ProSomnus Product Portfolio Delivers OSA Solutions for a Variety of Patients ProSomnus's devices are preferred by patients, clinically effective and offer attractive economics to all stakeholders ProSomnus Iterative Advancement [IA] ProSomnus Continuous Advancement [CA]
Slide 35: Purposely Designed Oral Appliance Addressing Limitations of Alternatives
STRICTLY CONFIDENTIAL 35 Prosomnus Purposely Designed an Oral Appliance that Addresses the Limitations of Alternative Therapies All comparison in relation to legacy OAT devices 1 1. 2020 AADSM Conference abstract Titration Mechanism: 90 Degree Maintains prescription if patient opens mouth during sle
Slide 36: More Patient-Friendly Alternatives and DTC Marketing Have Transformed Established Markets
STRICTLY CONFIDENTIAL 36 $29 $233 2017A 2021E $45 $3,942 2001A 2021E More Patient - Friendly Alternatives and DTC Marketing Have Transformed Established Markets Before Consumers are pre - positioned to act on ProSomnus’s DTC marketing in Dental / OSA market following decades of investment from peers
Slide 37: Incumbent Therapies Do Not Meet Continuous Physiologic Monitoring Needs
STRICTLY CONFIDENTIAL 37 Incumbent Therapies Do Not Meet Continuous Physiologic (Oxygen) Monitoring Needs of Sleep Medicine ProSomnus will be the first therapy to achieve continuous physiologic monitoring ADHERENCE POSITION AIRFLOW x x x x X X x X X x x X Legacy OAT ProSomnus (Q4 2022) CPAP Upper Ai
Slide 38: Non-GAAP Adjusted EBITDA Reconciliation
STRICTLY CONFIDENTIAL 38 Non - GAAP Adjusted EBITDA Reconciliation $ in millions FY2021A Net Income / (Loss) (6)$ (+) Foregiveness of PPP Loans (2) (+) Other Expenses (Income) 0 (+) Interest Expense 3 (+) Provision for Income Tax Expense 0 (+) Depreciation and Amortization 1 (+) DeSPAC Costs & Selec